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FIGURE 1 Patient Series
Images are for patients 1 to 4 in respective columns. (1A, 2A, 3A, 4A) Computed tomog-
raphy of mitral annular calciﬁcations. (1B) Three-dimensional transesophageal echocardi-
ography of valve implantation within the mitral annulus. (2B, 3B, 4B) Fluoroscopy of valve
implantation within the mitral annulus. (1C, 2C, 3C, 4C) Computed tomography post-
implantation. (1D) Three-dimensional echocardiography post-implantation. (2D, 3D, 4D)
Two-dimensional echocardiography post-implantation.
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2558training in transseptal catheterization and complex
mitral valve interventions.
A circular deployment of the balloon-expandable
device is obtained despite the saddle-shape geome-
try of the mitral annulus, and the tissue cushioning
surrounding the annulus may avoid the incidence
of paraprosthetic regurgitation. However, extensive
and protruding calciﬁcation may lead to peripro-
sthetic leaks.
The initial data on follow-up are encouraging;
however, potential concerns may relate to the risks
of atrial displacement and valve thrombosis.
This preliminary series suggests that transvenous
TMVR is feasible in inoperable patients with severe
mitral valve disease and MAC, particularly in those
with previous AVR, and may provide early and
midterm clinical and hemodynamic improvement. It
opens a discussion, and many issues are still to be
resolved. Further conﬁrmation may have an impor-
tant impact given the prevalence of severe MAC in
elderly patients and the technical difﬁculties of sur-
gical treatment.*Dominique Himbert, MD
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13:1205–6.Effectiveness of
Antitachycardia Pacing
for Recurrent Ventricular
Tachycardia in ARVCIn their prospective study of the North American
Arrhythmogenic Right Ventricular Cardiomyopathy
(ARVC) Registry, Link et al. (1) reported a 92% success
rate with antitachycardia pacing (ATP) in terminating
recurrent ventricular tachycardia (VT) in 48 patients
with an implantable cardioverter-deﬁbrillator (ICD)
who experienced a total of 489 sustained mono-
morphic VT episodes. The beneﬁt of ATP appeared
to be independent of the VT cycle length.
FIGURE 1 Beneﬁt of Endo-Epicardial Substrate–Based
Catheter Ablation in Preventing Recurrent VT in Patients
With Arrhythmogenic Right Ventricular Cardiomyopathy
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Data are derived from a pooled analysis of 4 studies (2–5)
including 160 patients (87 undergoing endocardial-only [Endo]
ablation and 73 undergoing endo-epicardial [Endo-Epi] ablation).
VT ¼ ventricular tachycardia.
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2559Although these ﬁndings would support program-
ming ATP for all patients with ARVC and an ICD, it is
important to report data on the actual number and
percentage of patients (rather than VT episodes) that
received only ATP, the average number (and range)
of appropriate ICD shocks per patient, and the num-
ber of patients and arrhythmia episodes that were
excluded from the analysis due to incomplete device
interrogation data and/or were lost to follow-up. The
number of ATP-treated episodes did not appear to be
uniformly distributed in the study population, with
7 patients having more than 20 episodes each and
1 patient experiencing 96 episodes. Analyzing the
efﬁcacy of ATP as a percentage of VT episodes suc-
cessfully terminated, rather than the percentage of
patients who had only ATP-treated episodes, may
overemphasize the beneﬁt of ATP in preventing ICD
shocks, which represents a major treatment focus
in patients with recurrent VT. If the 38 shocks
after ATP failed occurred throughout the study
group, this would probably be considered unsatis-
factory arrhythmia control. If, however, the shocks
occurred only in patients with very frequent VT and
therefore only rarely per overall arrhythmia burden,
this might be more acceptable.
Additional details on the ICD programming zones
and the management of recurrent VT during follow-
up would also be valuable to evaluate the impact
of different strategies (device reprogramming, anti-
arrhythmic medications, and/or invasive ablation
procedures) on the reduction of appropriate ICD in-
terventions and/or VT burden. In our experience,
antiarrhythmic medications have limited efﬁcacy in
controlling recurrent VT in patients with ARVC,
which is in line with data from a prior report of the
North American ARVC Registry. More aggressive ATP
programming may result in more VT acceleration, and
it would be helpful to know if this occurred and how
often. In the current report, there were 38 shocks
after failed ATP, 50 VT episodes that were treated
with shock initially, and 41 episodes of inappropriate
ICD therapy, resulting in 129 shocks in 108 patients.
Even if more aggressive ATP worked in a few more
patients, these results must certainly result in poor
quality of life, and we must try to improve on this
reported outcome in patients with ARVC.
Endo-epicardial substrate–based catheter ablation
has been shown to provide excellent intermediate-
term survival free from recurrent VT in the major-
ity of patients with ARVC, and the results have
been consistent across institutions and operators
(Figure 1) (2–5). In these patients, catheter ablation
typically results in a striking reduction in ICD
interventions for VT. Because the device is thenprogrammed to a high rate of cutoff, inappropriate
shocks are also avoided.
In conclusion, although the study by Link et al. (1)
suggests that ATP is highly effective in terminating
most cases of VT in patients with ARVC, this should
not be considered synonymous with “preventing ICD
shocks in 92% of patients.” ATP is rarely uniformly
effective when patients have very frequent VT
episodes. On the other hand, aggressive endo-
epicardial VT ablation that includes substrate
modiﬁcation with catheter ablation has been shown
to result in prevention of recurrent VT and therefore
any ICD interventions in most cases. The best
treatment strategy in this setting still needs to be
determined; until then, catheter ablation should be
strongly considered as an important part of the
treatment strategy in patients with ARVC and VT.*Pasquale Santangeli, MD
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2012;5:111–21.REPLY: Effectiveness of Antitachycardia
Pacing for Recurrent Ventricular Tachycardia
in ARVCDrs. Santangeli and Marchlinski have asked that we
clarify and expand on the treatment of arrhythmias
described in our recent report (1). We appreciate
this opportunity to respond.
Of the 108 patients with implantable cardioverter-
deﬁbrillators (ICDs) included in the registry, 48 pa-
tients had 502 sustained and treated episodes of
ventricular arrhythmia. Forty-three patients under-
went antitachycardia pacing (ATP) attempts for
ventricular tachycardia (VT); the other 5 patients
received only shock therapy. The number of ATP
attempts per patient ranged from 1 to 96; 28 patients
had #10 attempts. Forty-two of the 43 patients had
at least 1 successful ATP treatment for VT. Twenty-
seven patients had only successful ATP treatment.
Only 3 patients had more failed ATP attempts than
successful ATP attempts. Thus, programming the
ICDs to ﬁrst deliver ATP resulted in the avoidance of
shock treatment in a signiﬁcant number of patients,
and there were no fatalities. We stand by our
conclusion that “all ICDs should be programmed for
ATP, even for rapid VT” (1). However, ATP was not
always successful, because 16 patients had at least
1 ATP failure that resulted in an ICD shock. In total,
30 patients had 89 ICD shocks (average: 3; range: 1
to 9). We are not aware of any episodes of
arrhythmia that were excluded; all episodes of
arrhythmias reported to us were included in our
analysis. It is possible that there were episodes of
ICD shocks and ATP that were not reported to us
and thus could not be included in our analysis.
Drs. Santangeli and Marchlinski also requested
details on ICD programming and management of
recurrent VT during follow-up. In this registry, ICD
programming was left to the discretion of the
physician performing implantation and follow-up.
We do not have details regarding the lower rate
programmed for VT or the duration of VT for
which the ICD would have attempted treatment.
Fifty-three of the 108 patients with an ICD were
treated with antiarrhythmic drugs, and the detailshave been reported in another paper (2). Brieﬂy, in
this patient population, 58 patients who were
treated with beta-blockers did not have an increased
or decreased risk of arrhythmia. Treatment with
sotalol (n ¼ 38) was associated with an increased
risk of ventricular arrhythmias, and the 10 patients
treated with amiodarone had a signiﬁcantly lower
risk of ventricular arrhythmias. Fifteen patients
underwentablation.
Drs. Santangeli and Marchlinski commented on the
high efﬁcacy of the combination of endo-epicardial
catheter ablation. We agree that the reported data
show 1-year efﬁcacy of approximately 70%. We also
agree that the best treatment strategy regarding
recurrent VT remains to be determined, especially
with regard to ablation. In the population studied,
there was no attempt to prevent or promote ablation.
Indeed, 15 of the patients underwent ablation during
the study. However, we do not have data on whether
the attempts at ablation were endo-epicardial or on
the efﬁcacy of ablation in these patients.*Mark S. Link, MD
Douglas Laidlaw, MD
Bronislava Polonsky, MS
Wojciech Zareba, MD
Scott McNitt, MS
Kathleen Gear, RN
Frank Marcus, MD
N.A. Mark Estes III, MD
*Cardiac Electrophysiology
New England Medical Center
Box 197
750 Washington Street
Boston, Massachusetts 02111
E-mail: mlink@tufts-nemc.org
http://dx.doi.org/10.1016/j.jacc.2014.09.044
R EF E RENCE S
1. Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North
American Multidisciplinary Study of ARVC: predictors, characteristics, and
treatment. J Am Coll Cardiol 2014;64:119–25.
2. Marcus GM, Glidden DV, Polonsky B, et al. Efﬁcacy of antiarrhythmic drugs
in arrhythmogenic right ventricular cardiomyopathy: a report from the North
American ARVC Registry. J Am Coll Cardiol 2009;54:609–15.Obstructive Sleep Apnea
and Hypertrophic
Cardiomyopathy
Obiter Dictum or More?We read with interest the state-of-the-art paper
on the present and future of hypertrophic cardio-
myopathy (HCM) by Maron et al. (1), well-known
